PHCCC explained

PHCCC is a research drug which acts as a glutamate receptor ligand, particularly being a positive allosteric modulator at the mGluR₄ subtype,^[1] as well as an agonist at mGluR₆.^[2] It has anxiolytic effects in animal studies.^[3] PHCCC and similar drugs have been suggested as novel treatments for Parkinson's disease.^[4]

See also

• CPCCOEt

Notes and References

1. Maj M, Bruno V, Dragic Z, Yamamoto R, Battaglia G, Inderbitzin W, Stoehr N, Stein T, Gasparini F, Vranesic I, Kuhn R, Nicoletti F, Flor PJ . (−)-PHCCC, a positive allosteric modulator of mGluR4: characterization, mechanism of action, and neuroprotection . Neuropharmacology . 45 . 7 . 895–906 . December 2003 . 14573382 . 10.1016/S0028-3908(03)00271-5. 17446511 .
2. Beqollari D, Kammermeier PJ . The mGlu(4) receptor allosteric modulator N-phenyl-7-(hydroxyimino)cyclopropa[b]chromen-1a-carboxamide acts as a direct agonist at mGlu(6) receptors . European Journal of Pharmacology . 589 . 1–3 . 49–52 . July 2008 . 18593581 . 10.1016/j.ejphar.2008.06.054 .
3. Stachowicz K, Kłak K, Kłodzińska A, Chojnacka-Wojcik E, Pilc A . Anxiolytic-like effects of PHCCC, an allosteric modulator of mGlu4 receptors, in rats . European Journal of Pharmacology . 498 . 1–3 . 153–6 . September 2004 . 15363989 . 10.1016/j.ejphar.2004.07.001 .
4. Niswender CM, Johnson KA, Weaver CD, Jones CK, Xiang Z, Luo Q, Rodriguez AL, Marlo JE, de Paulis T, Thompson AD, Days EL, Nalywajko T, Austin CA, Williams MB, Ayala JE, Williams R, Lindsley CW, Conn PJ . Discovery, characterization, and antiparkinsonian effect of novel positive allosteric modulators of metabotropic glutamate receptor 4 . Molecular Pharmacology . 74 . 5 . 1345–58 . November 2008 . 18664603 . 10.1124/mol.108.049551 . 2574552.